Displaying drugs 601 - 625 of 15205 in total
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … reducing the signs and symptoms in patients 2 years old and older. ... It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and …
Ethyl ferulate
Approved
Experimental
Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …
Levomilnacipran
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …
Temocillin
Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.
Approved
Investigational
Matched Iupac: … thiophen-3-yl)acetamido]-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid …
Matched Description: … Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection. …
Matched Description: … Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection. …
Pegunigalsidase alfa
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and ... While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Aflibercept
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It...
Approved
Matched Description: … exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues ... it was approved by the FDA and EMA in August 2012 and February 2013, respectively. ... composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Estradiol acetate
Estradiol acetate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary ... a chance to enter systemic circulation and exert its estrogenic effects [A12102]. ... Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex …
Estradiol cypionate
Estradiol Cypionate is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream...
Approved
Investigational
Vet approved
Matched Description: … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary ... skin, prostate, bone, fat, and brain. ... a chance to enter systemic circulation and exert its estrogenic effects [A12102]. …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Tetradecyl hydrogen sulfate (ester)
Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins .
Sodium tetradecyl sulfate has been widely used since the 1950s, and in...
Approved
Matched Iupac: … [(7-ethyl-2-methylundecan-4-yl)oxy]sulfonic acid …
Matched Description: … is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose ... sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and ... Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report …
Matched Description: … is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose ... sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and ... Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report …
Sunitinib
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pomalidomide
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pascopyrum smithii pollen
Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Twenty-Two Standardized and Non-Standardized Grasses …
Susoctocog alfa
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the...
Approved
Investigational
Matched Description: … B domain replaced with a twenty-four amino acid linker. ... These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this ... Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for …
Matched Categories: … Blood and Blood Forming Organs …
Matched Categories: … Blood and Blood Forming Organs …
Torasemide
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Iupac: … carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-yl]formamido}-3-(3-methanesulfonylphenyl)propanoic acid …
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Betiatide
Approved
Experimental
Matched Iupac: … 2-(2-{2-[2-(benzoylsulfanyl)acetamido]acetamido}acetamido)acetic acid …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … neutralizes several RSV A and B strains. ... antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and ... the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Iodohippurate sodium I-131
Approved
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents …
Levetiracetam
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918]...
Approved
Matched Description: … It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated ... [L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no ... choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Cefixime
Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Investigational
Matched Iupac: … -[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … , and meningitis. ... a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and ... [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation …
Matched Categories: … cefixime and ornidazole ... cefixime and azithromycin …
Matched Description: … , and meningitis. ... a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and ... [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation …
Matched Categories: … cefixime and ornidazole ... cefixime and azithromycin …
Ceftobiprole
Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA).
The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Iupac: … 3E,3'R)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene]methyl}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …
Displaying drugs 601 - 625 of 15205 in total